NIH-funded study of people with type 1 diabetes shows safety, efficacy benefits of new system
A multicenter randomized clinical trial evaluating a new artificial pancreas system – which automatically monitors and regulates blood glucose levels – has found that the new system was more effective than existing treatments at controlling blood glucose levels in people with type 1 diabetes. The trial was primarily funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health.
The study showed that the system improved participants’ blood glucose control throughout the day and overnight. The latter is a common but serious challenge for children and adults with type 1 diabetes, since blood sugar can drop to dangerously low levels when a person is asleep. The research is published in the New England Journal of Medicine.
The artificial pancreas, also known as closed-loop control, is an “all-in-one” diabetes management system that tracks blood-sugar levels using a continuous glucose monitor (CGM) and automatically delivers the hormone insulin when needed using an insulin pump. The system replaces reliance on testing by fingerstick or CGM with separate delivery of insulin by multiple daily injections or a pump.
The International Diabetes Closed-Loop (iDCL) Study involves five separate artificial pancreas clinical protocols implemented by 10 research centers in the United States and Europe. This six-month study was the third phase in a series of trials. It was conducted with participants living their usual day-to-day lives, so the researchers could best understand how the system works in typical daily routines.
“Testing the safety and effectiveness of new technologies in real-world settings is critical to prove the usability of these systems by people with diabetes to achieve a better daily control of their blood glucose levels,” said Guillermo Arreaza-Rubín, M.D., director of NIDDK’s Diabetes Technology Program and project scientist for the study. “Earlier technologies have made the management of type 1 diabetes easier, and this research shows that this artificial pancreas system has the potential to improve health of people living with type 1 diabetes, while also potentially lifting much of the burden of care from those with the disease and their caregivers.”
This iDCL protocol enrolled 168 participants age 14 or older with type 1 diabetes. They were randomly assigned to use either the artificial pancreas system called Control-IQ or sensor-augmented pump (SAP) therapy with a CGM and insulin pump that did not automatically adjust insulin throughout the day. Participants had contact with study staff every two to four weeks to download and review device data. No remote monitoring of the systems was done, so that the study would reflect real-world use.
The researchers found that users of the artificial pancreas system significantly increased the amount of time with their blood glucose levels in the target range of 70 to 180 mg/dL by an average of 2.6 hours per day since beginning the trial, while the time in range in the SAP group remained unchanged over six months. Artificial pancreas users also showed improvements in time spent with high and low blood glucose, hemoglobin A1c, and other measurements related to diabetes control compared to the SAP group. High adherence to device use in both groups and 100% participant retention were important strengths of the study. During the study, no severe hypoglycemia events occurred in either group. Diabetic ketoacidosis occurred in one participant in the artificial pancreas group due to a problem with equipment that delivers insulin from the pump.
The Control-IQ technology was derived from a system originally developed at the University of Virginia, Charlottesville, (UVA) by a team led by Boris Kovatchev, Ph.D., director of the UVA Center for Diabetes Technology with funding support from NIDDK. In this system, the insulin pump is programmed with advanced control algorithms based on a mathematical model that uses the person’s glucose monitoring information to automatically adjust the insulin dose. Tandem Diabetes Care has submitted the results to the U.S. Food and Drug Administration for approval to market the Control-IQ system.
“This artificial pancreas system has several unique features that improve glucose control beyond what is achievable using traditional methods,” said Kovatchev. “In particular, there is a special safety module dedicated to prevention of hypoglycemia, and there is gradually intensified control overnight to achieve near-normal blood sugar levels every morning.”
Kovatchev was co-lead author of the study with colleagues Sue A. Brown, M.D., of UVA and Roy Beck, M.D., Ph.D., from the Jaeb Center for Health Research, Tampa, Florida, which was the coordinating center for the study.
“Artificial pancreas technology has tremendous potential to improve the day-to-day lives of people with type 1 diabetes,” said NIDDK Director Griffin P. Rodgers, M.D. “By making management of type 1 diabetes easier and more precise, this technology could reduce the daily burden of this disease, while also potentially reducing diabetes complications including eye, nerve and kidney diseases.”
The Latest on: Artificial pancreas
via Google News
The Latest on: Artificial pancreas
- Artificial Pancreas Device System Marketon June 18, 2020 at 8:17 am
The Insight Partners analysts forecasts the latest report on “Global Artificial Pancreas Device System Market (Covid-19) Impact and Analysis by 2025”, according to report; The Artificial ...
- Startup Gets $1.14 Million to Develop Artificial Pancreas Componenton June 16, 2020 at 5:00 pm
Pacific Diabetes Technologies's dual-function glucose sensing and insulin delivery system combines a sensing catheter, electronic sensor module, and insulin infusion line. A leading juvenile diabetes ...
- Woman Gets Diabetes, Builds Own Pancreason June 16, 2020 at 5:00 pm
Why not make the state of the insulin pump a function of the data? And thus, a sort of artificial pancreas. The project is open source for anyone to use and improve upon. She was placed on a list ...
- ADA: Medtronic's next-gen artificial pancreas algorithm boosts time in range for young adults with Type 1 diabeteson June 15, 2020 at 4:25 am
A new version of Medtronic’s advanced, hybrid closed-loop insulin delivery system showed it could help improve blood sugar control throughout the day in adolescents and young adults with Type 1 ...
- Gloves Aren’t Just For Covid-19: This One Can Be Used To Help Diabetes Patientson June 13, 2020 at 7:03 am
Gloves and masks have become the norm when leaving the house and we have all become very preoccupied with our health and that of our friends, families, neighbours and acquaintances — even the random ...
- Artificial Pancreas Market Share, Size 2020 Dynamics, Forecast, Analysis and Supply Demand 2025| Says Research Reports Worldon June 12, 2020 at 1:29 am
Global Artificial Pancreas Market (2020-2025) Industry Research Report focuses on the global Artificial Pancreas ...
- Impact of the COVID-19 pandemic on Artificial Pancreas Devices System Market to Achieve Significant Growthon June 11, 2020 at 5:00 pm
Global Artificial Pancreas Devices System Market report it provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe.
- Pancreas - Latest News and Research Updateson June 9, 2020 at 5:00 pm
The findings, involving new mouse models of Barth syn New Artificial Pancreas System: Life-changing Support to Type 1 Diabetes People New study is pioneering a new artificial pancreas system that ...
- Feasibility of Outpatient Fully Integrated Closed-Loop Control First Studies of Wearable Artificial Pancreason June 6, 2020 at 5:00 pm
Objective—To evaluate the feasibility of a wearable artificial pancreas system, the Diabetes Assistant (DiAs), which uses a smart phone as a closed-loop control platform. Research design and ...
- Fully Integrated Artificial Pancreas in Type 1 Diabeteson June 1, 2020 at 5:00 pm
These two randomized crossover studies of CLC in type 1 diabetic patients demonstrate 1) the feasibility of fully integrated subcutaneous CLC in a clinical setting, 2) the utility of modular ...
via Bing News